Evidence map›Paper›PMID 31097586›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2019

TrxR1, Gsr, and oxidative stress determine hepatocellular carcinoma malignancy.

Michael R McLoughlin, David J Orlicky, Justin R Prigge, Pushya Krishna, Emily A Talago, Ian R Cavigli, Sofi Eriksson, Colin G Miller, Jean A Kundert, Volkan I Sayin and 9 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 95 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Oxidative Stress and Age-Related Tumors.Antioxidants (Basel, Switzerland) · 2024
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Michael R McLoughlinDepartment of Microbiology and Immunology, Montana State University, Bozeman, MT 59718.
David J OrlickyDepartment of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045.ORCID 0000-0002-0417-1400
Justin R PriggeDepartment of Microbiology and Immunology, Montana State University, Bozeman, MT 59718.
Pushya KrishnaDepartment of Microbiology and Immunology, Montana State University, Bozeman, MT 59718.
Emily A TalagoDepartment of Microbiology and Immunology, Montana State University, Bozeman, MT 59718.
Ian R CavigliDepartment of Microbiology and Immunology, Montana State University, Bozeman, MT 59718.
Sofi ErikssonDepartment of Microbiology and Immunology, Montana State University, Bozeman, MT 59718.
Colin G MillerDepartment of Microbiology and Immunology, Montana State University, Bozeman, MT 59718.
Jean A KundertAnimal Resources Center, Montana State University, Bozeman, MT 59718.
Volkan I SayinDepartment of Pathology, New York University School of Medicine, New York, NY 10016.
Rachel A SabolDepartment of Microbiology and Immunology, Montana State University, Bozeman, MT 59718.
Joshua HeinemannDepartment of Chemistry and Biochemistry, Montana State University, Bozeman, MT 59718.
Luke O BrandenbergerDepartment of Microbiology and Immunology, Montana State University, Bozeman, MT 59718.
Sonya V IversonDepartment of Microbiology and Immunology, Montana State University, Bozeman, MT 59718.
Brian BothnerDepartment of Chemistry and Biochemistry, Montana State University, Bozeman, MT 59718.
Thales PapagiannakopoulosDepartment of Pathology, New York University School of Medicine, New York, NY 10016.
Colin T ShearnAnschutz Medical Campus, University of Colorado Denver, Aurora, CO 80045.
Elias S J ArnérDivision of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institute, 171 77 Stockholm, Sweden.ORCID 0000-0002-4807-6114
Edward E SchmidtDepartment of Microbiology and Immunology, Montana State University, Bozeman, MT 59718; eschmidt@montana.edu.ORCID 0000-0002-9959-4990
Montana State University · USNew York University · USUniversity of Colorado Anschutz Medical Campus · USKarolinska Institutet · SETulane University · US

Funding

Research Core (Developmental Research Project Program)P20GM103474 · NIGMS · MONTANA STATE UNIVERSITY - BOZEMAN · PI Jeffrey Good · 2012 to 2026
$60.0M
Pilot Grants ProgramP30GM110732 · NIGMS · MONTANA STATE UNIVERSITY - BOZEMAN · PI QUINN, MARK T · 2014 to 2018
$5.4M
Mechanisms of arsenic detoxification by the human microbiomeR01CA215784 · NCI · MONTANA STATE UNIVERSITY - BOZEMAN · PI Seth T Walk, Qian Wang · 2017 to 2026
$2.7M
Impact of hepatocyte lineage life history dynamics on liver homeostasis in the agR01AG040020 · NIA · MONTANA STATE UNIVERSITY - BOZEMAN · PI GEDEON, TOMAS, SCHMIDT, EDWARD E · 2011 to 2015
$1.5M
Metabolic basis of the NADPH-independent disulfide reductase system in mouse liverR01DK123738 · NIDDK · MONTANA STATE UNIVERSITY - BOZEMAN · PI DENICOLA, GINA MARIE, SCHMIDT, EDWARD E · 2020 to 2022
$1.3M
Hepatocyte-targeted somatic-cell genetic complementation in miceR21OD026444 · OD · MONTANA STATE UNIVERSITY - BOZEMAN · PI SCHMIDT, EDWARD E · 2019 to 2020
$396k
Redox regulation in the hepatostatR21AG055022 · NIA · MONTANA STATE UNIVERSITY - BOZEMAN · PI ARNER, ELIAS S.J., NAGY, PETER · 2016 to 2017
$382k
Initiation, persistence, and progression of hepatocellular carcinomaR21CA152559 · NCI · MONTANA STATE UNIVERSITY - BOZEMAN · PI SCHMIDT, EDWARD E · 2010 to 2011
$310k
NCI NIH HHS R01 CA215784NCI NIH HHS R21 CA152559NIA NIH HHS R01 AG040020NIA NIH HHS R21 AG055022NIDDK NIH HHS R01 DK123738NIGMS NIH HHS P20 GM103474NIGMS NIH HHS P30 GM110732NIH HHS R21 OD026444
6 · The paper itself

Abstract

Thioredoxin reductase-1 (TrxR1)-, glutathione reductase (Gsr)-, and Nrf2 transcription factor-driven antioxidant systems form an integrated network that combats potentially carcinogenic oxidative damage yet also protects cancer cells from oxidative death. Here we show that although unchallenged wild-type (WT), TrxR1-null, or Gsr-null mouse livers exhibited similarly low DNA damage indices, these were 100-fold higher in unchallenged TrxR1/Gsr-double-null livers. Notwithstanding, spontaneous cancer rates remained surprisingly low in TrxR1/Gsr-null livers. All genotypes, including TrxR1/Gsr-null, were susceptible to

Indexed as

AnimalsAntioxidantsCarcinoma, HepatocellularDisease ProgressionDNA DamageGene Expression RegulationGlutathioneGlutathione ReductaseHepatocytesLiverLiver NeoplasmsMaleMetabolomeMiceNF-E2-Related Factor 2Oxidation-ReductionAntioxidantsGlutathioneGlutathione ReductaseNF-E2-Related Factor 2Thioredoxin Reductase 1Txnrd1 protein, mouseglutathione reductasehepatocellular carcinomaNrf2oxidative stressthioredoxin reductase

Identifiers

PMID31097586
PMCPMC6561278
OpenAlexW2945880281

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.